|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Characteristics and prognosis of synchronous multiple early gastric cancer显示文摘AIM:To assess the clinicopathologic characteristics,risk factors,and prognosis for synchronous multiple early gastric cancer(SMGC).METHODS:A total of 146 patients with SMGC and1194 patients with single gastric cancer who had undergone gastrectomy between 1989 and 2008 were retrospectively analyzed to determine their clinicopathologic characteristics and postoperative survival.Tumors were classified into groups on the basis of location and histology.Smoking habits were evaluated using the Brinkman index.Clinical and pathological factors were compared using either Fisher’s exact test or Pearson’sχ2test.Logistic regression analysis was performed to identify independent risk factors.Survival rate was calculated using the Kaplan-Meier method.RESULTS:SMGCs accounted for 10.9%of gastric cancer cases and occurred predominantly in elderly male patients with a family history of gastric cancer who were both smokers and drinkers.These tumors were typically macroscopically elevated and histologically differentiated.There were no significant differences between SMGC and single gastric cancer patients with respect to tumor location,tumor size,lymph node metastasis,the number of metastatic lymph nodes,venous invasion,or tumor stage(P=0.052,P=0.347,P=0.595,P=0.805,P=0.559,and P=0.408,respectively).Further,there was no significant difference in postoperative survival between the patient groups(P=0.200).Of the 146SMGC patients,a single patient had remnant cancer.CONCLUSION:A careful preoperative endoscopy is necessary for patients who are at high risk of SMGC,and minimally invasive treatment may be indicated in some cases. | Taro Isobe Kousuke Hashimoto Junya Kizaki Naotaka Murakami Keishiro Aoyagi Kikuo Koufuji Yoshito Akagi Kazuo Shirouzu | 2013 | World Journal of Gastroenterology2013，19，41： | 17 |
| 2 | Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer显示文摘AIM: To clarify the significance of vascular endothelial growth factor(VEGF) in peritoneal metastasis from gastric cancer, using the gastric cancer cell line MKN-45 compared with the high potential peritoneal dissemination gastric cancer cell line MKN-45 P. METHODS: The supernatant of culture medium of MKN-45 cells or MKN-45 P cells was collected and the concentrations were measured of various cytokines, matrix metalloproteinases, growth factor and angiogenic factors, including VEGF. We performed an initial pilot study to explore whether bevacizumab, a humanized monoclonal antibody against VEGF, had any suppressive effect on the peritoneal dissemination from gastric cancer in an experimental nude mouse modelof peritoneal metastasis. RESULTS: The concentrations of interleukin-6(IL-6), IL-8, VEGF and matrix metalloproteinase-2 protein in the culture supernatant were each significantly higher than each of those for MKN-45. In the in vivo study, the volume of ascites and the mitotic index were significantly lower in the therapy group than in the nontherapy group. The survival curve of the therapy group was significantly higher than that of the non-therapy group. These results suggested that VEGF was correlated with peritoneal metastasis from gastric cancer. CONCLUSION: Findings suggested that bevacizumab for inhibiting VEGF could suppress peritoneal dissemination from gastric cancer. | Keishiro Aoyagi Kikuo Kouhuji Motoshi Miyagi Junya Kizaki Taro Isobe Kousuke Hashimoto Kazuo Shirouzu | 2013 | World Journal of Critical Care Medicine2013，2，4： | 12 |
| 3 | Molecular targeting to treat gastric cancer显示文摘Trastuzumab that targets human epidermal growth factor receptor 2(HER2) protein is the only approved molecular targeting agent for treating gastric cancer in Japan and the outcomes have been favorable. However,trastuzumab is effective for only 10% to 20% of the population with gastric cancer that expresses HER2 protein. Molecular targeting therapy with bevacizumab against vascular endothelial growth factors(VEGF) and with cetuximab and panitumumab against the epidermal growth factors pathway that have been approved for treating colorectal cancer are not considered effective for treating gastric cancer according to several clinical trials. However,ramucirumab that targets VEGF receptor-2 prolonged overall survival in a large phase Ⅲ clinical trial and it might be an effective molecular targeting therapy for gastric cancer. The significance of molecular targeting therapy for gastric cancer remains controversial. A large-scale randomized clinical trial of novel molecular targeting agents with which to treat gastric cancer is needed. | Keishiro Aoyagi Kikuo Kouhuji Junya Kizaki Taro Isobe Kousuke Hashimoto Kazuo Shirouzu | 2014 | World Journal of Gastroenterology2014，20，38： | 5 |
| 4 | Characteristics and prognosis of gastric cancer in young patients显示文摘 | Taro Isobe Kousuke Hashimoto Junya Kizaki Motoshi Miyagi Keishiro Aoyagi Kikuo Koufuji Kazuo Shirouzu | 2013 | Oncology Reports2013，，1： | 2 |
| 5 | Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer显示文摘 | Kousuke Hashimoto Keishiro Aoyagi Taro Isobe Kikuo Kouhuji Kazuo Shirouzu | 2014 | Gastric Cancer2014，，1： | 2 |
| 6 | Effects of Angiotensin II Type 1 Receptor Blocker on Albumin-Induced Cell Damage in Human Renal Proximal Tubular Epithelial Cells显示文摘 | Takao Toshihiro Horino Taro Kagawa Toru Matsumoto Reiko Inoue Kousuke Taguchi Takafumi Morita Tatsuhito Iwasaki Yasumasa Hashimoto Kozo Terada Yoshio | 2009 | American Journal of Nephrology2009，，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员